SCHEMBL19636552

SCHEMBL19636552

CCCCCCCCCNCC[C@H](C)CCCCCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
ALDH1A1 P00352 1/20 0.56
ACE2 Q9BYF1 1/20 0.47
ADH1B P00325 2/20 0.44
ADH1C P00326 2/20 0.44
ADH1A P07327 2/20 0.44
ADH4 P08319 2/20 0.44
ADH7 P40394 2/20 0.44
S1PR2 O95136 5/20 0.42
S1PR4 O95977 5/20 0.42
S1PR1 P21453 5/20 0.42
S1PR3 Q99500 5/20 0.42
S1PR5 Q9H228 1/20 0.42
EPHX1 P07099 3/20 0.41
OPRM1 P35372 1/20 0.39
ANPEP P15144 1/20 0.38
ERAP2 Q6P179 1/20 0.38
PRKD3 O94806 1/20 0.38
PRKCG P05129 1/20 0.38
PRKCB P05771 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23869885 0.96 TSHR (0.50) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL20427541 0.96 TSHR (0.62) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL12478863 0.96 TSHR (0.62) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL18615410 0.96 TSHR (0.62) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL18721219 0.96 TSHR (0.62) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL12479972 0.96 TSHR (0.62) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL20130405 0.93 TSHR (0.59) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL27254703 0.93 ALDH1A1 (0.59) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL24653400 0.93 TSHR (0.59) TSHRALDH1A1ACE2ADH1BADH1C
SCHEMBL21952707 0.91 ALDH1A1 (0.56) TSHRALDH1A1ACE2ADH1BADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017201347-A1 POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS MODERNATX, INC. (US) 2017-11-23 WO disclosed